click enter text
sept issu monthli controversi report
report cover bull/bear case current controversi rel growth
prospect us eu global pharmaceut compani
overal sector view individu compani fundament gener upward
trajectori uncertainti futur us price partli hold group back sector
rate market-weight
peer perform acquisit improv abbv outlook cliff
flatten see model good bad aspect deal see report
see price-to-earnings multipl equal dividend yield big pharma name
astrazeneca outperform long-term ep growth peer
averag must stock cash flow problem self-limit
bristol-my squibb outperform celg deal add controversi
controversi execut full pipelin price-to-earnings multipl expand modestli
eli lilli peer perform solid lt prospect stock sideway ahead
oral sema launch full revenu come diabet
glaxosmithklin peer perform plaudit chang thing eventu
consum spin-out unlock valu worth watch
merck outperform expect keytruda high still
sourc upsid under-model intenational opportun see report
reason price upcom fevipipr read probabl
peer perform upjohn spin-off destroy valu short term posit
better long-term despit big declin still cheap enough excit us
roch peer perform usual tug-of-war prospect
biosimilar exposur hard like good compani ep growth
model lowest group
sanofi peer perform hope trade underway new manag step
downsid support low valuat hard forget san
long histori often valu trap mayb time differ
factset/wolf research price sept
report limit sole use client wolf research pleas refer disclosur section locat end
www wolferesearch com/disclosur write us wolf research llc lexington avenu suit new york ny
analyst certif disclosur
page
tabl content
page
overal perspect global pharma sector exhibit gener
temper view drug industri overal name name basi compani enter
better period ahead industri fundament mix posit side gener product trend
 phase success rate among biopharmaceut compani turn last sever
year yet sever cover compani still late-stag pipelin thin rel much
spend annual rel larg size seem overcapac
mani compani chase smaller residu opportun posit collect
loe burden improv ahead anoth round big expir later emerg market
grow like gangbust china driver risk ala pfe upjohn neg
side us drug price remain spotlight creat near-term uncertainti next execut
order exampl long-term uncertainti next presid mean
long-term us drug price group would probabl act better werent uncertainti
term valuat group trade modest discount rel price-to-earnings multipl basi
total sharehold return basi outlook reason averag ep growth average ep compound-annual-growth-rate
averag dividend yield lead us sector rate market weight
exhibit overal perspect global pharma sector
page
major theme exhibit show think major theme sourc
news flow anticip next
exhibit major theme anticip
drug price outlook varieti propos continu promulg histori suggest mani
like die vine scale back less oner propos
effect lobbi effort deep-pocket drug industri coupl congression inertia
impact reform measur gener requir new law congress much shorter list chang
accomplish administr execut order rule-mak process hh
agenc commerci side payer dynam differ public program side price
govern principl natur competit oppos govern regul
misconcept think privat payer simpli follow footstep govern despit
privat commerci payer nonetheless effect foster signific price competit sever
instanc one genuin risk contempl next presidenti cycl depend outcom
substant polici chang could enact remain sourc uncertainti go
presidenti elect talk unsurprisingli surfac among democrat singl payer system
would bad healthcar subsector biopharmaceut fortun
much basi realiti opinion among democrat toward mix
page
partial list potenti case actual chang date includ
rebat reform trump administr propos ban pbm rebat medicar dead
could resurfac enact rule would like net posit drug industri
financi also perspect rais awar conflict interest within drug
channel downstream manufactur
medicar part began allow medicar advantag plan manag part drug
close broadli bipartisan support shift away tradit buy bill
framework arguabl skew physician incent physician may ultim taken
mix allow payer better manag type drug one propos benchmark price
basket intern price invari lower us price like becom
realiti view smaller tweak aim dismantl current part paradigm like
continu made
medicar part make meaning chang part seem possibl passag new
law earlier propos rule address six protect class drug insul
aggress payer action essenti disintegr
medicaid state medicaid program seek waiver grant author use
tradit formulari manag tool like formulari tri lower drug spend almost
alway lower profit channel biopharmaceut compani alreadi older drug
particular profit may actual non-exist medicaid spend drug roughli
state-level initi lack feder action individu state increasingli take
matter hand come initi tackl drug price exampl california
drug price transpar bill requir justif drug price increas certain level
push gener includ biosimilar free-market solut problem
free-market approach idea foster price competit make sure gener
approv bottleneck clear part roadblock greater biosimilar usag
evalu view reform-lit someth industri would gener
support lesser evil
exhibit use think impact us reform could global pharmaceut
compani even though data put us drug spend relat global drug spend
show split payer channel us global drug spend us repres
total us simplist carv two main bucket commerci public
program take-away impact small chang us program get dilut given
global revenu mix mnc
page
exhibit summar compani exposur us payer channel vari meaning
exhibit payer exposur us drug busi compani
valuat perform exhibit show forward price-to-earnings multipl coverag univers rel
last left rel price perform coverag univers vs
last right
page
exhibit valuat perform rel
compar growth rate exhibit show rel revenu ep growth rate cover
compani index three differ time period shown
view accur
page
exhibit compar revenu ep growth rate
page
view view view reveneu growth ep growth ep growth reveneu growth ep growth revenu growth
exhibit base revenu analysi look growth profil cover compani collect
product market today exclud futur pipelin drug includ revenu divis
consum health anim health diagnost across two differ period intent
exhibit show longer stretch time compani biggest futur loss
contend usual due patent expir drug compani long-rang plan take
consider think much spend put behind potenti target
key point make
view differ view least compani
smaller pure play compani tend fastest growth also tend volatil
base revenu
compani fortun enough posit base revenu growth least next
sever year patent expir cycl
basi mani move neg growth territori order magnitud includ
exhibit base revenu growth shown bmi celg abbv agn pro-forma estim
page
exhibit comp sheet cover stock certain large-cap therapeut name also shown
refer
factset wolf research price note estim exclud celg estim exclud
page
celg excl upjohn azn w/o europ healthcar compani comparison cover pharma target multipl
rate price target summar exhibit
azn novn rate outperform like azn best novn
one notch lower lower long-term ep growth rel three
gsk san rate peer perform gsk look
intrigu us
exhibit wr summari rate price target
factset wolf research price
page
companyratingpric pt multipl epsu/d price astrazeneca azn squibb nv novn vx opchf rhhbi rog vx ppchf sni sasi pa pp average average return vs
pp pt acquisit gener controversi last time
saw price-to-earnings multipl equal dividend yield
compani report factset wolf research price
page
wolf bullet-point view
investor sentiment investor tri figur stock follow june
announc acquisit consensu yet
pipelin prowess abil best acquisit allergan improv
 capabl abbv phase compound natur
binari event risk possibl ftc interven neg way forc divestitur skyrizi
agn phase assur wont happen explan seem reason
near-term outlook growth near- intermediate-term decent never problem
long-term concern stori domin pend merger
long-term outlook fold improv long-term outlook provid stabl base
howev preliminari pro-forma model still show flat-to-slightly-declin rev ep
better terribl excit
valuat low price-to-earnings multipl basi stand-alon includ tie
net long time felt big deal would eventu necessari solut
outlook better find posit neg transact
posit side revenues/ep trajectori post better acquir collect product
reason valuat neg side wont like bring much tabl term
transact essenti realli big spec pharma roll-up smack pure financi
engin pro-forma price-to-earnings multipl basi stock indisput cheap ev/ebidta multipl
predict paint differ pictur inexpens stori seem devoid catalyst investor
still left uncertainti model us humira biosimilar us humira still account
total revenu biosimilar entri near-term possibl
unexpect ftc intervent consid last time saw forward price-to-earnings multipl equal
dividend yield big drug compani alon make abbv/agn reason compel
announc acquisit mavupharma privat compani focus target sting
pathway cancer treatment disclos deal term
report result beat revenu ep expect rais guidanc gave
impress sale guidanc skyrizi ee global pharmaceut full
postview anoth rais
submit nda elagolix heavi menstrual bleed associ uterin fibroid
page
competitor news us district court rule sandoz enbrel patent
favor outcom humira near-term threat enbrel biosimilar entri remov
fda approv upadacitinib ra patient inadequ respons intoler
approv requir box warn seem less sever xeljanz mortal olumi fatal
thrombosi attribut thrombosi risk jak class relat instead specif upadacitinib
announc discontinu rova-t develop program due surviv benefit
demonstr interim analysi meru trial sclc prompt idmc recommend
trial termin market move away care product long ago
announc io collabor idera pharmaceut explor variou combo therapi
involv abbv agonist idera agonist tilsotolimod hnscc
import upcom event next
label chang label augment guidelin updat posit find ecog trial
expect data file fda label chang
competitor event azn acalabrutinib vs ibrutinib genom high-risk
r/r cll elev trial acalabrutinib read later
azn announc june combo acalabrutinib obinutuzumab significantli
improv cll elevate-tn trial
read-out aml top-lin data readout end earli detail data unlik
upadacitinib jak data
wolf research inaugur healthcar confer ny novemb manag
attend click regist view agenda
humira biosimilar eros monitor multipl eu biosimilar enter octob us
biosimilar start enter januari multipl entrant throughout year samsung
avastin biosimilar herceptin us offer anoth opportun gaug futur eros dynam
page
closur deal guidanc earli
meaning fix abbv humira problem stock cheap given new profil
shore long-term model help absorb humira loe valuat low
enhanc financi profil healthi dividend yield
humira biosimilar concern fulli discount even eu biosimilar launch global
brand continu grow next year margin high estim global oper
margin also expir roch cabilli patent lessen royalti pay partial
offset eu eros us biosimilar dont launch long way away
commerci potenti franchis under-appreci leverag exist humira
relationship secur favor payer access physician prescript skyrizi rinvoq
alreadi describ favor access skyrizi earli launch product
b-cell tumor franchis imbruvica/venclexta great outlook imbruvica venclexta
solid high margin high growth product albeit one captur partial econom
combin use product could boost share sever patient popul
acquisit repres classic financi engin bring pipelin roll-up
master roll-up help bolster financi that pipelin enhanc
meaning strateg synergi still left linger growth problem onward
pipelin thin
help humira problem still still left uncertainti model
year us loe us humira still account pro-forma top-lin
manag multipl downward misguid ex-u eros show even manag
underestim downward trajectori could extend larger us market well manag
purportedli acknowledg meet investor faster eros origin expect may lay
ftc requir skyrizi divestitur ftc move bmy/celg otezla show agenc
thing break preced even though reason point circumst skyrizi
vs agn brazikumab differ yet clear ftc fulli sign
case may need divest skyrizi keep agn brazikumab develop
ibd uc cd wolf comment think risk like low in-lin describ
opioid litig risk abbv/abt say indemnifi purduebut happen purdu goe
away say wont specul hypothet
page
imbruvica import off-set humira could potenti unseat follow-on btk inhibitor
oncolog product clearli better data quickli displac older product azn head head
data earliest late wolf comment later-gener btk inhibitor realli materi better
convinc data lack moment
total pro-forma revenu
humira variou autoimmun disord world biggest drug reliabl
consist sourc growth year face uncertainti eu discount thwart
biosimilar high
imbruvica variou b-cell malign lead asset pcyc acquisit big
product big growth expect continu monitor gener btk possibl threat
agn botox multipl therapeut indic aesthet legaci specialti drug
patent protect ingredi manufactur process protect trade
secret claim due highli technic natur molecul unlik see biosimilar
howev jeuveau launch earli credibl threat botox aesthet
market support non-inferior data vs botox
mavyret hcv abbv market-lead hcv offer global sale may alreadi
peak gaug rate declin
agn juvederm collect aesthet collect multipl product includ
voluma ultra ultra etc facial filler base hyaluron acid mainli lip augment
minim face wrinkl creas think juvederm sale could surpass botox
pipelin asset gener later-stag candid visibl higher includ
in-depth discuss manag see report highlight pipelin
unplug call chief scientif offic product shown
upadacitinib jak indic expans true pipelin product per se oral select
inhibitor approv ra psoriat arthriti crohn diseas ulcer coliti atop dermat
although label indic inadequ respons intoler miss -nave
similar xeljanz better olumi box warn seem less sever lack product specif
thrombosi risk attribut jak class vs xeljanz olumi label mortal risk xeljanz label
asset clearli within abbv domain expertis manag guid ww sale
model way third-in-class serv indic heavi brand
increasingli gener competit
page
skyrizi indic expans true pipelin product per se recent approv psoriasi
develop ad hs cd uc clinic profil compar jnj tremfya guselkumab
offer conveni dose schedul vs anoth import product fill humira
footstep manag guid ww sale model way
entrant class serv indic heavi brand increasingli gener competit
imbruvica btk indic expans true pipelin product per se approv cll mcl mzl
waldenstrom macroglobulinemia gvhd push earlier line treatment new tumor
type follicular lymphoma activ cll less activ outsid cll alreadi multi-billion-dollar
blockbust product good growth ahead far lead vs btk big downsid risk
gener btk azn acalabrutinib abl demonstr superior
consensu expect econom share
venclexta indic expans true pipelin product per se approv r/r cll
without del expans earlier line cll treatment tumor type aml mm
mcl partli live imbruvica shadow novel highli activ drug kol academ
center embrac drug fear pervad within commun set around drug safeti profil
low risk tumor lysi syndrom probabl deserv attent receiv today howev
partial clinic hold place fda dampen hope expand mm market great opportun
broadli combin imbruvica one two punch econom share roch
page
growth profil decent help blunt hit humira us biosimilar
valuat current price-to-earnings lowest alongsid bmi celg pro-forma basi full comp sheet
see exhibit stand-alon basi trade price-to-earnings multipl ep
ep ep pro-forma basi price-to-earnings multipl even lower
use target price-to-earnings multipl appli stand-alon ep arriv year end
price target pro-forma basi price target impli price-to-earnings multipl approxim
abbv agn ep estim use price target multipl across cover compani rang
abbv incom statement revenu forecast balanc sheet/cash flow statement see appendix
financi statement end report
page
astrazeneca azn op pt long-term ep growth group averag plu pipelin
option take-out potenti approach bump road china busi
compani report factset wolf research price
page
wolf bullet-point view azn
investor sentiment gener attract azn futur growth prospect understand avers
extern feel like cook book on-going controversi on-going weak cash flow
pipelin prowess histor great compani deliv better last
sever year variou asset phase commonli view major pipelin stori
binari event risk lower relat pipelin read-out perhap china risk given big presenc
near-term outlook usher ep growth increasingli organ china growth like
impact due relat reform see slide emerg market
momentum china ruin parti slide emerg market
long-term outlook strong long-term outlook growth compar durabl mani
compani face big loe event
valuat expens nearer-term ep price-to-earnings normal out-year given superior growth
net continu like azn best long-term grower group turn around
margin expans stori new growth come already-approv product
mean azn heavili depend futur pipelin traction unpredict said
azn still late-stag pipelin opportun ahead investor expect overli high
mean upsid like exce downsid also like two aspect azn footprint
china greater compani uncertainti nearer-term due china
drug price reform potenti azn could one day take-out target one smaller
compani sector recal pfe attempt azn cash flow remain weak moment
problem resolv assum growth continu current trajectori
also chmp gave posit recommend self-administr fasenra new
pre-fil autoinjector devic help level play field san dupix
competitor event gsk announc zejula improv progression-fre surviv patient
given mainten follow chemotherapi ovarian cancer prima trial investor
compar prima like-for-lik biomark segment septemb trial
azn report solid financi result rais product sale guidanc left ep
guidanc intact china oncolog major driver detail pleas see global
 azn full postview quarter growth stock rariti pharma
page
azn announc lynparza prolong progression-fre surviv subset mcrpc patient
atm gene mutat profound trial result qualifi partial success
lynparza use extend new tumor type azn hope would benefit broader set patient
ddr defect mcrpc patient either brcamt atmmt full detail
esmo septemb
azn announc tagrisso improv overal surviv previou soc egfrmt nsclc
flaura trial argu unappreci sourc downsid risk azn
biggest drug full scientif result esmo septemb
azn announc lynparza improv progression-fre surviv patient ad avastin
mainten ovarian cancer trial azn promis biomark subgroup analys
acknowledg necessari interpret full scientif result esmo septemb
back-to-back gsk prima
azn announc imfinzi/tremelimumab improv overal surviv compar standard
chemotherapi nsclc patient high tumor mutat burden neptun
trial end tmb probabl
chines regul nmpa approv roxadustat non-dialysi depend chronic kidney
diseas ndd-ckd roxadustat approv ckd patient dialysi decemb azn
partner fibrogen china expect launch roxadustat china
delic word press releas azn announc anifrolumab met primari endpoint
bicla respons patient lupu sle trial august azn disclos
anfrolumab fail parallel trial employ differ respons endpoint
reduct disease-act describ clinically-meaning azn plan explor pathway
bring anifrolumab market
esc congress pari azn present full detail two major cardiovascular outcom
trial themi dual antiplatelet therapi brilinta patient type diabet establish
stabl coronari arteri diseas essenti dud contrast dapa-hf landmark trial
establish farxiga heart-failur drug farxiga ad standard care patient hfref
reduc composit primari endpoint hr individu compon
 worsen heart failur hr cv death hr reach statist
signific all-caus death also reduc hr nomin formal signific
order endpoint benefit consist across subgroup differ
diabet non-diabet patient receiv entresto result
buttress futur growth farxiga loe us farxiga first-in-ind among
class lli jardianc emperor-reduc year behind pcd june
 azn farxiga esc highlight call discuss impress dapa-hf
result entresto
chines regul nmpa approv tagrisso egfrmt nsclc china
import market tagrisso sinc hold egfrmt patient tagrisso approv
egfrmt nsclc gain reimburs indic
page
wclc azn present full detail imfinzi sclc caspian first top-lin
posit late june azn second market year behind ahead still
although surviv benefit mo hr mirror achiev tecentriq secondari
measur like orr favor imfinzi may help negat first-mov advantag
import upcom event next
nsclc trial poseidon investor expect low especi post neptun failur
mean upsid downsid poseidon look similar bmi
durva treme chemo arm along durva chemo chemo combo arm often over-look
inform see global pharmaceut slide lung cancer trial
watch azn poseidon neptun
trial continu tumor type like scchn kestrel bladder cancer danub
himalaya role combo azn futur
set tbd thu far work grand total zero indic
line-expans trial ovarian mainten combin avastin patient full
detail septemb esmo profound biomarker-select full detail septemb
esmo competitor zejula prima ovarian mainten hrd patient present
time
roxadustat anemia efficaci safeti trial read next step us regulatori
submiss octob investor expect remain mix partli checker histori
compound anemia/epo/esa space also commerci dynam dialysi market
entrench competit pre-dialysi treatment market doesnt realli exist china launch
roxadustat select price negoti ahead inclus recent nrdl updat
calquenc cancer full detail elevate-tn poor-risk cll probabl decemb
import head-to-head trial elevate-r/r abbv imbruvica r/r high risk cll
come earli nccn alreadi recommend r/r cll clear us physician use alreadi
indic investor cautious optimist calquenc truli differenti
trastuzumab cancer file post convent mbc start
asset behind daiichi sankyo collabor
farxiga hfref indic expans regulatori file soon possibl hfref back
impress dapa-hf result launch end assum standard review
page
wolf research inaugur healthcar confer ny novemb azn manag
particip inform click regist view agenda
growth china attenu due program azn exposur geographi
highest among peer compani point toward slow-down later
emerg market momentum china ruin parti emerg market
best lt ep growth big pharma first mani year lead ep growth
importantli growth come newer base approv product word azn
futur growth heavili depend futur pipelin success difficult call
margin expans stori azn cost structur heavili out-of-whack follow period heavi patent
expiri burden expiri move background organ growth return due
variou import new product launch tagrisso farxiga imfinzi lynparza fasenra lead
natur margin expans substanti
heavi exposur oncolog one hottest diseas area azn exposur oncolog
grow place concentr diseas area second
high-growth high-margin market segment cover compani want increas
exposur
heavi exposur china import em azn exposur china around
total product sale exposur higher peer group azn said margin china
better margin europ despit sell price china much lower exampl
tagrisso price china lower us azn recent struck deal gain coverag
china nrdl addit content subject see slide emerg
market momentum china ruin parti emerg market
take-out potenti tri move big strateg mistak get
deal close view compani could still come knock howev short list
point mayb
china big disappoint due azn give assur contrari note
pulmicort wont put tender innov brand growth help off-set expos product like crestor
page
extern artifici ep boost stock even expens alreadi appear
practic sourc controversi sinc began manag wont say
time-frame ramp acknowledg peak ramp creat
tough comp given high profit dollar
margin expans alreadi bake consensu doesnt deliv wolf comment
admittedli margin expans big pharma tend elus commonplac
flow weak limit busi develop appropri re-invest compani
wit azn recent unusu move issu equiti fund smaller deal wolf comment weak cash
flow certainli new concern led birth extern
ceo pascal soriot leav press report look previous join teva
azn board director initi formal search replac yet pascal seem
minim flight risk ask
outlook biggest market product collect total revenu
tagrisso cancer overtak symbicort azn largest drug especi
import asian market like japan china egfrmt nsclc patient found
synerg well azn market-lead china penetr small molecul drug royalti burden
symbicort asthma/copd tail end life cycl face addit
indirect pressur gener us advair symbicort gener show model best guess
farxiga diabet one three franchis gener expect
competit strong jardianc invokana formal indic hfref
dapa-hf next catalyst growth possibl indic expans gener ckd dapa-ckd
late upsid
brilinta cv steadi grower within approv indic
nexium gerd azn biggest drug nexium sustain
post-lo drug ex-u ex-eu revenu
pipelin asset gener later-stag candid visibl higher includ
in-depth discuss leadership see report global pharmaceut azn highlight
pipelin unplug call senior leadership
page
tagrisso anti-egfr tki mtegfr nsclc indic expans true pipelin drug per se
lock soc secur os benefit data esmo septemb azn look expand non-
metastat diseas laura crt consolid adaura adjuv trial investor
given one much thought yet evid anti-egfr tki yield benefit set
lynparza parp variou cancer indic expans true pipelin drug per se lynparza
co-develop merck alreadi approv ovarian cancer mani studi
set on-going predict good efficaci variou cancer ovarian tnbc pancreat recent
brca mutat express infrequ azn/mrk tri expand tumor
brca limit combin therapi exist medicin avastin imfinzi
keytruda well pipelin product azn dna damag repair ddr portfolio includ
agent inhibitor atm inhibitor azn
claim commerci futur compound underestim
roxadustat oral hif-ph anemia azn us/china right complex three-way partnership
astella eu origin cardiovascular safeti demonstr pool result
trial like olympu non-dialysi ckd mace non-inferior vs placebo rocki dialysi
critic assess risk/benefit ultim commerci posit us file plan
octob china launch reimburs provid price found
tezepelumab anti-tslp mab asthma novel biolog block master regul asthma
inflamm pathway recd breakthrough therapi design data asthma suggest efficaci
regardless eo level holi grail excit mechan enter potenti crowd market
share econom trial run pathfind navig result
calquenc acalabrutinib btki mcl cll indic expans true pipelin drug per se
acerta acquisit go market leader imbruvica virtual
monopoli btki space azn hope differenti safeti ascend r/r cll btki
secur formal label though exclus domin drug cloud posit
import elevate-tn like decemb uniqu monotherapi arm
genom high-risk elev compar imbruvica
trastuzumab deruxtecan trastuzumab like kadcyla put design
mechanist advantag phase data heavili pretreat breast cancer show
orr appar durabl month median durat link compar kadcyla
convent breast mariann rog trial fail beat herceptin plu chemotherapi
antidot excess exuber azn lay develop strategi three layer
advanc refractori convent breast gastric cancer expand wider
breast cancer market low explor segment nsclc
azn expect submit convent breast cancer co-develop
co-commerci collabor ex-japan daiichi sankyo
page
imfinzi /-tremelimumab unclear imfinzi treme ever approv fail improv os
nsclc mystic patient neptun high btmb scchn
eagl data indic scchn bladder come would enter
io experienc market new trial azn build pacifc success look imfinzi alon
non-metastat diseas nmibc mibc sclc nsclc cervic combin
chemotherapi sclc caspian posit detail wclc biliari tract cancer initi aegean
neo-adjuv nsclc first report caveat trial start possibl slippag
anifrolumab life yet program failur first trial tulip investor
larg discount seem promis pipelin drug employ differ composit
respons endpoint bicla instead use azn abl claim statist signific
clinic meaning reduct diseas activ tulip howev leav azn
singl posit trial regul requir azn claim consist effect across trial
measur use bicla enough persuad regul extend flexibl
growth profil mark turn-around azn growth return
valuat highest group full comp sheet see exhibit azn trade price-to-earnings multipl
ep ep ep use target price-to-earnings
multipl appli ep arriv year end price target use price target
multipl across cover compani rang
azn incom statement revenu forecast balanc sheet/cash flow statement see appendix
financi statement end report
page
bristol-my squibb op pt ach good news sort
surpris reliabl execut pipelin price-to-earnings multipl see modest expans
compani report factset wolf research price note estim exclud celg
page
wolf bullet-point view
investor sentiment among unlov stock on-going io uncertainti controversi celg
pipelin prowess pipelin among best group thank celg term
internally-develop candid remain interest celg asset quit interest
balanc except ozanimod
binari event risk event risk pend io read-out upsid downsid point
given low expect binari event risk celg also clearli feed setback
pipelin otherwis would impact share advers
near-term outlook hold pattern deal close late financi result decent
shape opdivo seem like contract period revert lt growth
long-term outlook celg offset depend opdivo final slow combin
organ much higher growth vs stand-alon follow
descent due cliff investor continu focu neg
valuat bmi price-to-earnings multipl pro-forma celg estim meaning lower peer group
tie abbv agn
net certainli controversi rate volatil
stock tie mishap immuno-oncolog space lost major lead
merck space date back continu controversi long-term
trajectori opdivo uncertainti price plausibl scenario opdivo continu
remain one two market lead therapi valu temporari period
contract seem probabl given recent trend success part give treatment
regimen differenti mrk keytruda chemo combo await full data like esmo
septemb understand right place nsclc rais odd posit data
three sourc long-term option upsid broader anti-pdx categori rememb
adjuv data next gen asset may work combin ex-u opportun possibl
under-model see report may azn ex-u
opportun substanti under-model probabl celg still struggl say like
transact remov take-out potenti buy addit patent cliff cap
multipl despit stock seem oversold base pro-forma valuat invest thesi
primarili rest idea pipelin excit gener drive drug stock perform
bmy/celg perhap fullest late-stag pipelin among cover compani
compound highli novel ozanimod except emphasi ad bmy/celg execut
pipelin modest price-to-earnings multipl expans current depress level would
provid investor suitabl return still leav bmy/celg appropri big discount peer
discount deserv bmy/celg combin futur patent cliff
page
announc highli anticip top-line result part part
nsclc part opdivo chemo arm fail part opdivo yervoy arm posit
patient met co-primari endpoint os part opdivo yervoy patient also
show surviv benefit although secondari endpoint expect regulatori file
base part although data part also includ
result unexpect twist net posit provid differenti regimen
report earn beat revenu ep ep guidanc rais despit
strong result analyst attent squar focus result releas night
sourc differenti
bempegaldesleukin pegyl agonist treatment previous untreat
unresect metastat melanoma registr data melanoma expect
fda grant breakthrough therapi design
nektar news announc manufactur issu two lot bempegaldesleukin
like advers impact result phase trial nektar indic neither
aberr lot use registr trial opdivo bempegaldesleukin collabor
expect includ indic compar previous anticip recal
entitl bempegaldesleukin global profit
celg news announc fda approv inreb fedratinib select inh
treatment myelofibrosi label includ black box warn seriou fatal encephalopathi
includ wernick seen treat patient clinic trial
announc divestitur otezla much higher street expect
proce larg use debt reduct also step acceler share repurchas
close merger late
import upcom event gener next
nsclc part part final os data present sept
readout opdivo cabometyx combo rcc earli could help level
play field yervoy-combo scchn yervoy-combo/chemo-combo
combo gastric adjuv readout opdivo yervoy melanoma opdivo
page
mono bladder opdivo mono esophag opdivo bempegaldesleukin
competitor io read-out azn poseidon similar structur cm-
look durva treme chemo durva chemo
liso-cel fda submiss expect readout durabl data full
transcend enrol complet pivot data present
decemb
fedratinib recent approv us myelofibrosi eu submiss year end
top-line result expect seem unlik decemb fda
submiss expect
luspatercept fda pdufa beta-thalassemia-associ anemia decemb
prioriti review mds-associ anemia pdufa april standard review eu accept
beta-th md
ozanimod fda pdufa march rm ema decis rrm
north trial uc readout
wolf research inaugur healthcar confer ny novemb manag
attend inform click regist view agenda
celg deal closur end
patent challeng eliqui made progress eliqui ip litig settlement mylan
januari remov overhang ipr patent expir tradit patent
challeng continu howev lower court trial expect begin follow split markman
decis court adopt posit one construct defend posit
revlimid celg patent litig celg enjoy ptab win addit settlement seem
like allow phase gener entri start
competitor event celg ozanimod ipr challeng biogen tecfidera late-d patent
method ms treatment expiri subject ipr ptab decis februari
invalid would bring gener entri forward year like commod market
page
celg bring much fuller phase pipelin provid near-term catalyst long-term
revenu stream mani repres novel cutting-edg scienc
valuat low despit controversi trade singl digit price-to-earnings multipl pro-forma estim
level abbv agn
still big player io lung surpris success opdivo yervoy
offer regimen differenti chemo-combo arguabl better scenario late-entr me-
follow-on weaker result vs view valu chemo free
regimen given gener avers chemo size segment possibl full result
releas come opdivo yervoy chemo odd almost higher
overal opdivo remain biggest product pdx categori bad posit
 result unexpect twist net posit provid
differenti regimen full postview result
data clear event sourc differenti
three long-term sourc io categori upsid would benefit two market leader
disproportion three long-term sourc import upsid io categori
mind adjuv opportun anti-pdx therapi get use earlier-stag diseas
would translat even bigger difficult quantifi market opportun potenti under-
model ex-u anti-pdx opportun base histor preced meaning cancer drug
usual sell outsid us us consensu current model revers
inform see global pharmaceut azn ex-u
opportun substanti under-model probabl industri final succeed find
synergist agent combin anti-pdx therapi make greater proport patient
respons therapi admittedli lot disappoint date front
celg deal portend bigger problem opdivo consensu expect mayb product
doesnt deliv lt growth like consensu model guid
acquir celg magnifi bmi exist long-term patent cliff exposur revlimid celg
phase eros start eliqui opdivo start
execut risk take celg asset might fall crack
deal-closur celg employe start look next job
disproportion sensit potenti us healthcar reform due product mix
among highest exposur coverag program like medicare/medicaid see exhibit
meaning reform program ep could disproportion hit
take-out thesi forev evapor post celg-deal closur
page
outlook biggest market product includ celg product collect five
account sale total pro-forma revenu
revlimid multipl myeloma md mcl fl mzl market lead imid
celgen cash cow also sourc content bmi celg deal given loe
eliqui stroke/dvt market-lead oral anti-coagul split growth
continu linearli displac warfarin target undiagnos untreat popul off-pat
opdivo cancer possibl probabl product goe ex-growth period
lung roll maintain long-term growth like depend indic outsid nsclc
altogeth ex-u opportun broadli off-pat time-frame
orencia autoimmun diseas matur product still grow crowd arthriti
market clear biosimilar competit sight
pomalyst multipl myeloma follow-up product revlimid limit multipl
myeloma thu far growth expect loss exclus expect eu us loe
hit
pipelin asset gener later-stag candid visibl higher includ
anti-bcma car-t celg registr karmma studi refractori mm fulli enrol
submiss potenti us approv bcma hot target mm multipl
compani leverag differ modal may easier use real world cell
therapi bear point lack disclosur recent updat data
luspatercept erythroid matur agent anemia celg phase trial md post epo
beta-thalassemia transfus depend read posit file approv us eu
accept myelofibrosi phase small imbal thromboembol
event seen betal-th trial overal fairli derisk point
opdivo yervoy indic expans true pipelin drug per se opdivo
approv mel nsclc rcc hodgkin scchn msi-h bladder variou trial
on-going host tumor type term combin approv mel
rcc posit like approv nsclc studi tumor type well
inh psoriasi result data decent
category-lead key oral therapi versu newer approv agent
page
inject destin becom even crowd space earlier phase evalu underway
includ lupu ibd crohn
liso-cel car-t celg us file rrdlbcl expect approv
registr trial cll recent start therapi alreadi competit yescarta
kymriah market although liso-cel data appear stronger
ozanimod rrm ibd celg fda refus file rrm earli due
insuffici nonclin clinic pharmacolog data refil eu fda complet
non-clin pk/pd bridg studi look major activ metabolit fda advisori committe
meet seem possibl phase ibd trial uc crohn on-going data
fedratinib inh celg recent approv fda myelofibrosi patient relaps
ruxolitinib jakifi includ black box warn seriou fatal encephalopathi includ
wernick phase polycythaemia vera ongiong eu file expect previous shelv
sanofi safeti concern celg acquir impact biomedicin reviv program
discov manufactur issu call question valid phase data led registr
program reason shaki phase data recent asco-gu shook
investor confid asset nektar say caus collabor narrow
indic compar expect phase trial combin opdivo start
melanoma data readout expect rcc phase trial plan bladder
nsclc other revis scope understood year
relatlimab phase trial combin opdivo mel data phase data
shown signal terribl strong one view
growth profil stand-alon pro-forma estim shown decent
toggl opdivo trajectori uncertain
page
exhibit celg pro forma mini-p adjust yet pend otezla divestitur
valuat current price-to-earnings lowest alongsid abbv-agn pro-forma basi full comp sheet
see exhibit bmi celg trade price-to-earnings multipl pro forma ep
pro forma ep pro forma ep begin think price target
bmi celg use pro forma number even though deal yet close price target impli
price-to-earnings multipl approxim pro forma bmi celg ep estim pro forma model
stand-alone compani trade price-to-earnings multipl ep
ep ep stand-alone compani use target price-to-earnings multipl
appli ep arriv year end price target use price target multipl
across cover compani rang
bmi incom statement revenu forecast balanc sheet/cash flow statement see appendix
financi statement end report
page
pp pt stock stuck ahead oral sema launch diabet total
compani report factset wolf research price
page
wolf bullet-point view
investor sentiment well-lik consensu buy short circl ahead oral
pipelin prowess histor one better organ late-stag pipelin
product tirzepatid near-term pipelin catalyst bit light armo pegilodecakin
binari event risk oral sema price gener expect closer inject vs oral oad
launch expect strong
near-term outlook loe headwind cialis/forteo mean like modest growth
year investor anticip novo oral sema launch think enough room glp multipl
product co-exist
long-term outlook solid one best long-term growth rate per current model
valuat come still among highest group price-to-earnings multipl basi
net like long-term outlook assum forecast right
increment posit stock give ground ahead oral sema perhap pull-back
rare high-growth pharma name investor take advantag problem
take month gain visibl commerci trajectori oral sema specif impact
lli all-import trulic visibl may occur lli exposur diabet
undeni high come total revenu therapeut categori price
competit happen continu monitor sidelin lean favor toward name
announc posit os data monarch trial verzenio combo
fulvestr hr metastat breast cancer base plan interim analysi regulatori
submiss data present expect year recal show os novn
respect compound
report earn higher revenu solid beat ep guidanc rais
detail see full postview rev higher beat ep remain
one best grower group
announc posit top-line readout emgal galcanezumab conquer studi
patient previous fail prevent treatment chronic episod migrain data
expect leverag payer reimburs discuss ex-u
page
announc us court appeal rule favor indic competitor dr reddi
hospira intend market altern salt form would infring alimta vitamin regimen patent
us exclus expect may patent upheld remain challeng
announc posit top-line result ixora-r trial demonstr superior taltz
tremfya jnj inh moder sever plaqu psoriasi base pasi measur
week pasi week secondari endpoint expect
announc posit top-line data studi olumi baricitinib moderate-
to-sever atop dermat third posit readout set five trial last two trial
expect readout end earli
announc fda approv taltz treatment radiograph axial spondyloarthr
approv base coast-v biolog nave coast-w tnf nonrespons intoler
present posit data phase studi selpercatinib
ret fusion-posit nsclc patient data posit registr post-platinum ret
fusion posit nsclc non-registr treatment nave cohort fda submiss expect
end ret-fus posit nsclc prior platinum-bas chemo selpercatinib
previous grant breakthrough therapi design indic
competitor event azn releas dapa-hf landmark trial establish farxiga
heart-failur drug result buttress futur growth farxiga loe us farxiga
first-in-ind among class lli jardianc emperor-reduc year
behind pcd june global pharmaceut azn farxiga esc highlight call
discuss impress dapa-hf result entresto
import upcom event next
lasmiditan submit fda like approv
pegilodecakin phase trial nsclc pegilodecakin keytruda
phase trial nsclc pegliodecakin opdivo complet readout phase
sequoia pancreat cancer readout
ret inhibitor posit phase studi nsclc present wclc thyroid
cancer readout come initi submiss ret fusion-posit nsclc expect
end ex-u market follow
jardianc diabet chronic heart failur phase studi assess exercis abil hfref
hfpef read emperor-hf larger phase chf outcom trial emperor-
reduc emperor-preserv measur composit cv death hospit heart
page
failur hfref hfpef respect readout us track design recent
competitor event approv novonordisk oral semaglutid competitor trulic
beyond assess competit label drug price import datapoint watch
novo seem consist signal somewher current brand oral inject
market assum closer pdufa septemb expect strong launch
believ trulic continu perform well despit manag previous told us
expect sourc busi oral sema inject
oral
one best ep grower lli smaller revenu base vs peer often almost
afford compani greater earn leverag new revenu stream growth name large-cap
bioharma pharma biotech rare creat scarciti valu
major margin expans stori deliv commit long-term spend target
first given say margin expans go forwardposs lot go
usher expans per guidanc
tirzepatid give long-term protect diabet franchis given
could multi-year lead competitor blood sugar control weight loss data category-lead
albeit shorter-dur trial
success would truli transform would send share straight noth stock
minu neg impact ep spend
lli diabet exposur liabil three differ front
price fierc price competit categori lli current overal exposur high total
compani sale divest elanco
polit insulin price spotlight may stay way insulin account
sale humalog alon account seem fda probabl use insulin first
opportun approv interchang ab-rat biosimilar per updat agenc guidanc
page
brand competit trulic face competit novo nordisk oral semaglutid also
heighten competit space azn success dapa-hf trial boost farxiga
high expect tirzepatid high potenti singl
trial shorter durat underli biolog well understood leav open question
long-term safety/efficaci also format anti-drug antibodi ada quit high dose
titrat total elimin investor concern
apart tirzepatid rest pipelin thin tanezumab opportun limit oa
pegilodecakin high-risk high reward hit lasmiditan enter crowd space ret inhibitor
high us government channel exposur among highest exposur peer group subject
risk chang us healthcar reform
outlook biggest market product collect total revenu
trulic diabet one two market-lead franchis strong growth prospect
humalog diabet tail end life-cycle face biosimilar us/eu
alimta cancer matur product grow much even increas usag
conjunct pdx eu alreadi face gener us gener
forteo osteoporosi tail end life-cycle face gener competit
taltz pso fourth year launch still go strong ramp pso potenti
addit indic expans axspa approv
pipelin asset gener later-stag candid visibl higher includ
dual incretin agonist diabet suddenli high expect
product stem placebo- active-compar random control data
look great better blood sugar control better weight loss toler moder wors
say dose titrat reduc investor keep mind howev singl
phase dose-rang trial launch phase trial includ nash mind
anti-drug antibodi ada potenti neutral drug clinic effect given structur
homolog exenatid long-term safeti also need monitor given uncertain biolog target
page
ret inhibitor cancer first-in-class ret inhibitor lli acquisit
loxo januari account price breakthrough therapi design ret-
fusion posit nsclc thyroid cancer ret-mut medullari thyroid cancer posit data
phase studi nsclc recent present wclc us submiss expect late
launch
lasmiditan acut migrain non-triptan oral therapi avoid vasoconstrict seem
caus dizzi paresthesia interest oral therapi acut attack
complement cgrp antagonist unclear label devoid standard triptan-lik cv warn
pegilodecakin cancer pegyl came armo
acquisit drug alreadi variou phase trial purportedli singl agent
activ first phase read sequoia pancreat cancer pegliodecakin folfox readout
admittedli higher risk phase nsclc complet readout
rcc expect start
tanezumab anti-ngf pain novel non-opioid mechan sever pain persist safeti
baggag rpoa pursu registr oa submiss chronic low back pain
abandon lucki get approv view
alzheim past failur solanezumab lanabecestat virtual everi compani
keep investor expect disease-modifi drug alzheim low scienc slowli
progress lli focu a-beta specif antibodi antibodi anti-tau antibodi
combo broadest ad platform compani
growth profil steadi high growth continu margin expans
valuat among highest group price-to-earnings multipl basi full comp sheet see exhibit
trade price-to-earnings multipl ep ep
page
ep use target price-to-earnings multipl appli ep arriv year end price
target use price target multipl across cover compani rang
lli incom statement revenu forecast balanc sheet/cash flow statement see appendix financi
statement end report
page
glaxosmithklin gsk pp pt shake thing futur split consum health
someth look forward
compani report factset wolf research price
page
wolf bullet-point view gsk
investor sentiment mix point view build appreci manag effort turn thing
pipelin prowess thinner side term late-stag product raw abil
total devoid bcma gsk promis turn around put new
leadership place step right direct
binari event risk event monitor go year-end bcma data zejula prima
probabl esmo end septemb expect medium asset zejula data fail impress
investor may beat gsk
near-term outlook ep growth neg due us advair gx tsro dilut
trough hiv uncertainti persist due competit consensu estim probabl need
come franchis
long-term outlook steadier ep growth trajectori commit eventu split
consum unlock valu manag say wont like occur
valuat price-to-earnings multipl shi group averag
net increment posit last sever month buy
case yet fulli gel compani activ tri chang thing win plaudit
old new approach one exampl includ commit split newly-form
consum albeit effect meaning chang big organ like gsk
easi histori show often fall flat dividend yield nearli pay investor wait viiv trend
requir continu monitor make investor nervou loss ground seem
occur us abroad compani pipelin thinner side upcom
read out may terribl inspir expect modest rais possibl
upsid downsid
gsk announc dovato met non-inferior maintain viral suppress compar taf-
contain regimen tango switch trial full result present ia juli
gsk announc zejula improv progression-fre surviv patient given
mainten follow chemotherapi ovarian cancer prima trial full result septemb
esmo back-to-back azn see strongli competit result may chang investor
view tesaro acquisit
page
ia updat tsepamo studi confirm associ dolutegravir
concept neural tube birth defect also ia gsk present follow-up juluca
gemini treatment-emerg resist observ
gsk report financi result ahead consensu rais ep guidanc head
research barron gave mini-upd global pharmaceut gsk full
postview result modest upward revis forecast
gsk announc jonathan symond succeed sir philip hampton non-execut chairman
board effect septemb pharmaceut industri experi former cfo novarti
astrazeneca welcom balanc senior leadership team assembl industri
gsk complet format chc jv although certain jurisdict transfer
asset gsk yet taken place chc revenu repres total
gsk announc departur bailey presid end
year maya martinez-davi formerli emd serono assum respons januari
background oncolog help launch success zejula ovarian mainten
potenti gsk mm
competitor event azn announc lynparza improv progression-fre surviv patient
ad avastin mainten ovarian cancer trial full detail
septemb esmo back-to-back prima
gsk announc posit top-line result belantamab mafodotin bcma
trial triple-refractori imid pi multipl myeloma
follow posit result gsk licens hbv antisens ioni fee mileston
import upcom event next
bcma antibodi drug conjug belantamab mafadotin full detail
triple-refractori multipl myeloma patient like us file end
zejula parpi prima ovarian mainten hrd patient full detail septemb us
mainten submiss end quadra ovarian pdufa octob competitor
azn/mrk lynparza whose trial set present back-to-back
session part tesaro acquisit
dostarlimab potenti us file endometri cancer end part tesaro acquisit
page
fostemsavir hiv regulatori submiss treatment-experienc hiv posit toplin
manufactur led delay lead compound among hiv asset acquir
esmo investor event webcast septemb edt discuss prima
horlicks/nutrit divestitur anticip end spin per management guidanc wolf
comment could time spin move offici time-frame split seem arbitrari
lengthi
sum-of-the-part basi gsk attract larger exposur consum health
sale follow jv consumm august appli compar price-to-earnings busi
use consum compani comp show impli price-to-earnings multipl gsk pharma/vaccin
busi low
ceo chang thing made lot outsid hire think luke miel barron kevin sin iain
mackay among other done one acquisit tsro busi develop activ
commit eventu spin consum health post jv format creat
hope trade demonstr proactiv manag team
dividend yield nearli higher group averag
threat hiv/aid franchis total sale key growth driver includ
gild biktarvi bictegravir ftc taf direct competit gsk tivicay/triumeq
take share us payer dynam may chang hiv drug class rebat move
higher wont led chang protect drug class statu gsk defens
so-cal two-drug regimen weak one may fear resist
suppli limit shingrix gsk say curtail growth new suppli open difficult
know analyst model correctli
turn around tall order especi new head live far away
gsk respect new head resid sf bay area long way stevenag uk
pennsylvania us gsk late-stag pipelin thinner side under-whelm data
bcma prima/zejula may kill enthusiasm may build
page
balanc sheet constrain gsk balance-sheet constrain lock high dividend
pay-out abil meaning beyond tsro way bring new asset limit
outlook biggest market product collect gbp total
triumeq growth slow near term gilead biktarvi continu
advair asthma/copd declin product final experienc first us gener
entri acceler declin even faster
tivicay remain decent grower near mid-term continu
face risk gilead biktarvi
shingrix shingl vaccin new vaccin whose efficaci blow competit
merck zostavax away great uncertainti suppli make growth hard forecast
relvar/breo asthma/copd slow grower near- mid-term crowd
payor-pressur respiratori inhal market
pipelin asset gener later-stag candid visibl higher includ
in-depth discuss leadership see report global pharmaceut gsk highlight
pipelin unplug call senior leadership
bcma antibodi drug conjug mafodotin multipl myeloma lead
way term drug-bas anti-bcma approach car-t bcma
bi-specif chase phase data gsk drug impress
show orr patient tripl refractori proteasom inhibitors/ immunomodulators/
daratuzumab full detail pivot trial data patient triple-refractori like
larg program combin trial start data trial start would
gsk first meaning cancer medicin almost exit area us breakthrough
therapi design award data
alfa co-develop/co-commerci mrk gr interest
compound appar better orr pdx small uncontrol trial thu far clinic
program includ pivot biliari cancer gutsi head-to-head
page
trial nsclc compar keytruda nsclc imfinzi
stage unresect nsclc latter two larg phase trial
expand size describ registr collabor gate
cabotegravir long-act integras inhibitor hiv treatment possibl prevent
hiv/aid gsk believ patient want inject altern daili oral formul
two separ im inject frequent pain day follow probabl mean choic
submit us everi dose pdufa decemb gsk also pursu
prevent high risk individu would quit novel unclear realist phase
trial compar inject cabotegravir gild truvada at-risk men readout
second phase trial women start
zejula parp variou cancer indic expans true pipelin drug per se lead asset
tesaro acquisit first parpi demonstr activ ovarian cancer outsid brcamt
subset near-term expans mainten monotherapi afford prima investor
physician judg rel lynparza/avastin similar trial analysi made easier
back-to-back present esmo gsk/tesaro also chase lynparza earlier success brcamt
tnbc bravo race alongsid combin drug like pdx first ovarian
novel ht magnitud gsk claim commerci futur compound underestim
fostemsavir attach inhibitor acquisit bmi hiv asset first-in-class drug
treatment-experienc hiv smaller commerci indic phase bright studi recent
toplin posit transfer manufactur delay regulatori submiss
anti-gm-csf ra fulli human antibodi compet crowd ra
space effect associ pain licens morphosi primari endpoint phase trial
statist signific present acr gsk encourag pain relief
initi parallel phase trial compar xeljanz ra crowd increasingli gener launch
dostarlimab human antibodi possibl week mainten dose
garnet studi dostarlimab produc durabl respons irrecist endometri cancer
regardless microsatellit instabl statu signal hold analyz prefer recist
criteria gsk plan file end nich opportun help pay tesaro acquisit
daprodustat hif-prolyl hydroxylas inhibitor anemia oral agent meant displac inject
epo/esa product similar azn roxadustat safeti data mix phase trial ascend-d
dialysi interim readout ascend-n non-dialysi readout
page
growth profil trough return growth thereaft reason
revenu boost due chc jv format late skew comparison
valuat current price-to-earnings multipl near group averag full comp sheet see exhibit gsk
trade price-to-earnings multipl ep ep
ep use target price-to-earnings multipl appli ep arriv year end price target
use price target multipl across cover compani rang
gsk incom statement revenu forecast balanc sheet/cash flow statement see appendix
financi statement end report
page
merck op pt crush io gardasil upsid good name
compani report factset wolf research price
page
wolf bullet-point view
investor sentiment morph consensu buy keytruda almost singular focu
pipelin prowess late-stag pipelin remain thin histor good core
compet potenti upsid see slide deserv credit nearli flawless
execut io continu outpac competit
binari event risk lower end mostli tie variou io trial readout azn
read out may allow entri lung would come mrk expens includ
bmi esmo azn poseidon earli
also adjuv read-out come differ tumor type play field level
compani clearli lead top-lin posit neo-adjuv tnbc alreadi
near-term outlook ep growth look competit bias upsid keytruda grow
faster expect gardasil continu deliv better-than-expect growth see report
topic gardasil major under-appreci growth driver under-model billion
long-term outlook long-term outlook solidifi nice one stock
cover capabl post doubl digit ep growth sever driver keytruda gardasil lynparza
possibl lenvima januvia loe use fear view manag
valuat modestli averag price-to-earnings multipl basi
net clearli becom consensu buy valuat still reason
context above-averag growth profil compar low event risk face
fulli expect remain io compani addit driver io upsid
worth exposur adjuv opportun next gen agent may combin
ex-u opportun like under-model see report may
azn ex-u opportun substanti under-model probabl
percept one growth driver keytruda incorrect view
gardasil second major futur growth driver still think consensu under-model
furthermor patent cliff vaccin meaning competit threat
horizon also claim lynparza azn lenvima eisai under-appreci
realli need round stori late-stag pipelin undeni thin
moment solv pipelin problem scrub biopharma landscap opportun
seem pauciti good bigger target view far earli bearish
keytruda lose patent protect late
competitor event gsk announc zejula improv progression-fre surviv patient
given mainten follow chemotherapi ovarian cancer prima trial investor
compar prima like-for-lik biomark segment present probabl esmo
page
announc fda approv recarbrio treat adult complic urinari tract
intradomin bacteri infect caus certain suscept gram-neg microorgan
present data ia show similar antivir activ doravirin combo
compar delstrigo wk
competitor event announc top-line result part part
nsclc part opdivo chemo arm fail part opdivo yervoy posit patient
met co-primari endpoint os part opdivo yervoy patient also show surviv
benefit result unexpect twist net posit
provid differenti regimen
announc posit pivot result neo-adjuv tnbc keytruda chemo
report strong result comfort beat consensu revenu ep rais
guidanc keytruda gardasil sale continu impress global pharmaceut
announc fda approv keytruda recurr local advanc metastat esophag
squamou cell carcinoma patient base result
announc posit profound result hrr mutation-select mcrpc lynparza met
rpf primari endpoint
announc posit result mainten advanc ovarian cancer
regardless brca-gen mutat lynparza w/bevacizumab met primari endpoint vs
receiv ec approv keytruda combo w/inlyta rcc imdc risk group base
remind fda approv april
competitor event top-lin result prevnar vaccin ped
remov uncertainti around program extens seemingli diminish commerci
potenti mrk compet although battl yet prevnar cross
mileston still await data dose lead time ped segment
import upcom event next
keytruda/io indic expans competitor read-out
read-out data present combo sclc mono/combo bladder
page
competitor read-out bmi part part data present esmo azn poseidon
trial bmi opdivo cabozantanib rcc bmi two cycl
chemo opdivo yervoy
profound data present septemb esmo
read-out adjuv brcamt breast cancer olympia
prevnar follow-on two adult trial read import
pediatr trial dont complet end readout like
lenvima tki rcc combo keytruda read-out april
interim analysi mrcc combo keytruda data present septemb esmo
gefapix chronic cough primari complet juli endometriosi relat pain primari
complet june
hiv combo primari complet oct
vericiguat heart failur studi complet aug data
wolf research inaugur healthcar confer ny novemb manag
particip inform click regist view agenda
 would fill pipelin seem thin said transform deal tabl
essenti defin tie-up w/ anoth larg pharma co impli option
tabl could still deal ten billion dollar rang
three long-term sourc io categori upsid would benefit two market leader
disproportion three long-term sourc import upsid io categori
mind adjuv opportun anti-pdx therapi get use earlier-stag diseas
page
would translat even bigger difficult quantifi market opportun potenti under-
model ex-u anti-pdx opportun base histor preced meaning cancer drug
usual sell outsid us us consensu current model revers see
azn ex-u opportun substanti under-
model probabl industri final succeed find synergist agent combin anti-pdx
therapi make greater proport patient respons therapi admittedli
lot disappoint date front
gardasil upsid still under-model old vaccin see renew life move beyond
std vaccin prevent hpv cancer vaccin also roll new geographi china
major driver gain broader label higher age rang gender neutral near
monopoli gsk product round error competit en rout smaller em
compani vaccin dont face gener competit first publish initi report claim
gardasil like substanti under-model consensu gap gardasil revenu
estim compar consensu see gardasil major under-
appreci growth driver under-model billion dollar sinc consensu estim
risen still lower vs estim see consensu increasingli get
gardasil opportun
one better ep grower valuat still reason doubl digit ep growth averag
januvia us loe single-year blip model
hidden upsid may abl make inroad market current domin pfe
prevnar odd lower pass poc program ped background
context see new prevnar better webcast replay
consensu buy keytruda opportun fulli built risk downsid competitor
gain traction azn other could slowli chip away metastat lung market share
depend variou upcom trial read adjuv set upcom read out could
shift market play field appear level across competitor moment
merck kgaa/gsk go keytruda bispecif fusion protein target
tgf- gsk sign partner februari phase studi complet octob
goe keytruda true head-to-head fashion spoke gsk manag
asset recent pipelin unplug call link wolf comment worth keep radar
present seem like remot risk data gener
keytruda goe patent late wolf comment full decad awaytoo far matter
eros mrk big base sever franchis face face commerci pressur either
brand loss exclus includ januvia price risk competit loe
start remicad biosimilar zetia/vytorin loe zostavax gsk
page
old use great dead keytruda simpli luck
bought sgp similarli sgp luck bought organon wit thin late-
stage pipelin despit spend variou setback last mani year
apart keytruda rare use fail trial
outlook biggest market product collect total revenu
keytruda cancer market-lead put pole posit within competit
lucr io market bmi opdivo still viabl alreadi blockbust we/consensu
expect drug doubl size off-pat time-frame
januvia/janumet diabet mrk biggest product keytruda class-lead
inhibitor matur brand face price pressur mount competit oral
therapi sale hold steadi despit said june analyst
meet compani still reliabl grow loe
gardasil hpv lead hpv vaccin gsk cervarix nearli round error
futur growth fuel china approv expans older popul also male demand outstrip
suppli work hard increas optim exist footprint addit
new product line gener risk never
bridion anesthet surgic anesthesia drug come schering-
plough acquisit one fred star seen sharp acceler recent year off-
isentress hiv first-gener integras inhibitor ex-growth due competit
newer agent gsk off-pat
pipelin asset gener later-stag candid visibl higher includ
keytruda approv alreadi variou cancer indic expans true pipelin
drug per se alreadi approv eleven tumor type inclus msi-high indic
way crucial driver futur compani growth expect high on-going success execut
thu far terrif
lynparza parp variou cancer indic expans true pipelin drug per se lynparza
co-develop azn alreadi approv ovarian cancer breast studi set
on-going predict good efficaci variou cancer brca mutat express
infrequ azn/mrk final succeed tumor brca limit recent posit paola-
result ovarian cancer azn claim commerci futur compound
page
lenvima multi-kinas inhibitor approv alreadi variou cancer indic expans true
pipelin drug per se new compound came deal eisai easi
overlook given book share revenu net commerci expens allianc
revenu approv thyroid cancer rcc addit on-going combo effort
rcc agreement call combin studi differ tumor type
endometri cancer non-smal cell lung cancer hepatocellular carcinoma head neck cancer bladder
cancer melanoma efficaci compel thu far think investor under-estim
pneumococc conjug vaccin next-gen vaccin evalu adult
pediatr offer two addit serotyp protect pfe class-lead two
phase adult trial read pediatr trial read howev next-gen
vaccin valent also work call question long-term relev mrk product
least adult less year ahead also signal patent present freedom-
to-oper challeng pediatr ahead mayb
gefapix chronic cough theoret larg patient popul radar
investor seem toler issu dysgeusia recent start highlight
asset frequenc overal pipelin thin concern aris
payer coverag side effect tast loss experienc major patient first two
chronic cough read
nrtti hiv diseas viral suppress prep first class nrtti moa inhibit
revers transcriptas potenti high barrier resist high rate intracellular persist due
high half-lif hour develop possibl weekli oral treat activ diseas monthli
oral yearli implant prep preliminari studi present ia
posit compar activ control two-drug combo doravivrin dor
mainten therapi week initi week treatment three-drug regimen dor
lamivudin expect complet oct info see
present juli slide hiv/aid paradigm shift soon tell
vericiguat sgc partner bayer advanc reduc eject fraction heart failur hfref
despit mix result studi complet seem get littl air time
variou earlier-stag io asset either wholly-own partner sting gitr
rig-i cavatak kra mek lot support data
far compani
growth profil consist solid top- bottom-lin grower
januvia us loe clip growth growth return downstream
page
valuat current price-to-earnings multipl modestli averag full comp sheet see exhibit trade
price-to-earnings multipl ep ep ep
use target price-to-earnings multipl appli ep arriv year end price target use
price target multipl across cover compani rang
mrk incom statement revenu forecast balanc sheet/cash flow statement see appendix financi
statement end report
page
novarti novn op pt chf catalyst-driven feel-good stock lt growth
modest
compani report wolf research price
page
wolf bullet-point view novn
pipelin prowess abil solid afraid cut edg pursu
current late-stag pipelin fairli full sever compound larg de-risk
binari event risk import near-term top-line fevipipr program asthma
registr exacerb reduct data feel like coin-toss impact stock
direct depend outcom read-out crizanlizumab spartalizumab like
matter less mayb ofatumumab look-alik rog ocrevu except self-administ could surpris
upsid full data releas
near-term outlook reason growth catalyst ahead like keep investor
engag zolgensma ramp watch close
long-term outlook growth competit beyond begin moder function
compani size pressur occasion
valuat modestli averag
net like novarti one easier stori tell identifi top
pick start surprisingli favor sentiment warm sinc
fairli full pipelin compar low risk profil good growth least new ceo
va narasimhan execut quarterli perform sinc take februari investor
like one rare ceo come therefor abl talk detail pipelin
catalyst ahead includ continu narrow focu alcon spun rumbl get rid
sandoz next variou pipelin read-outs/approvals/launch entresto track well becom
mani billion-dollar product investor alway hope could face least degre new
competit emerg class without hfpef expans opportun off-set
fevipir data repres import upsid hit belief upsid
downsid read-out long-term growth beyond struggl bit due current model
 perhap novarti final becom aggress take cost system way
boost ep investor would wise hold breath wait
novn partner discontinu two trial bacei alzheim
prevent base unfavour interim review show worsen measur cognit
function wr carri sale forecast
fda accept file crizalizumab prevent vaso-occlus crise
voc patient sickl cell diseas award prioriti review
page
novn report earn beat consensu sale ep rais core
guidanc across board full detail see global pharmaceut novn full postview
host ceo va narasimhan road follow earn convers
wide-rang see novarti convers ceo
novn announc entresto narrowli miss statist signific composit cv
death/tot hhf endpoint close watch paragon-hf trial hfpef full result
present esc septemb entresto reduc composit primari endpoint
entir reduct total heart failur hospit impact cv death
best entresto may gain limit off-label use patient midrang eject fraction benefit
somewhat greater
novn announc kisqali improv overal surviv combin fulvestr
trial mbc competitor announc cdki verzenio also improv os
analog previou day leav market leader ibranc cold trial
present back-to-back esmo septemb
fda disclos data integr issu zolgensma regulatori file maintain
support continu market use zolgensma novarti novn respond press releas
defend zolgensma held investor call discuss controversi link avexi knew
problem subsequ disclosur challeng novn timelin senat involv
